Royalty Pharma reports first quarter 2026 results
Royalty Pharma reported Q1 2026 Portfolio Receipts of $925 million, an increase of 10% year-over-year, driven by 13% growth in Royalty Receipts to $887 million. Net cash provided by operating activities grew 20% to $718 million, reflecting strong operational leverage. The company raised its full-year 2026 guidance for Portfolio Receipts to a range of $3,325 million to $3,450 million, up from the previous range of $3,275 million to $3,425 million. This update reflects expected Royalty Receipts growth of 4% to 8% for the year.
Key figures
- Revenue
- 925000000
- Guidance
- Portfolio Receipts $3,325 million to $3,450 million, raised from $3,275 million to $3,425 million
- Revenue Yoy
- 10%
- Adjusted ebitda
- 889000000
- Total dividends
- 136000000
- Royalty receipts
- 887000000
- Share repurchases
- 50000000
- Capital deployment
- 528000000
- Dividend per share
- 0.235
- Portfolio cash flow
- 722000000
- Royalty receipts yoy
- 13%
- Transaction announced value
- 1250000000
- Net cash operating activities
- 718000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.